◈ Nootpedia

This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Compact view
Research pass: thorough Compound WATCH-LIST HIGH

Injectable L-Carnitine

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Editor's verdict WATCH-LIST HIGH

For a healthy 20yo MMA athlete with no fat-loss goal, no carnitine deficiency, and no metabolic disease, injectable L-carnitine has no legitimate use case the oral form (already in stack discussions via ALCAR) doesn't cover at 1/100th the cost. The injection rationale collapses on inspection — (a) oral 1.5-3 g/day already produces 1.21 kg fat loss in meta-analysis (Pooyandjoo 2020); (b) the user is lean and doesn't have a body-composition target driven by carnitine; (c) injectable bypasses TMAO production but the TMAO concern is exactly why oral ALCAR is OPTIONAL-ADD with cycling — not a reason to escalate the route; (d) clinic injections cost $25-75 per shot vs ~$0.08/cap oral. The legitimate IV indications (PCD, ESRD, valproate toxicity) are clinical scenarios that don't apply. WATCH-LIST flips back into play only if (1) a documented carnitine deficiency emerges on bloodwork, (2) ESRD develops (not happening at 20), (3) a weight-loss-clinic program enters the picture for some reason, or (4) a head-to-head IM-vs-oral RCT for body composition shows IM produces a meaningfully larger effect (currently no such trial exists).

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • ★20-30, brain-priority, lean MMA athlete (this archetype)
    WATCH-LIST

    No legitimate use case the oral form doesn't cover at 1/100th the cost. Verdict only flips if (a) documented carnitine deficiency emerges on June bloodwork, (b) entry into a clinical weight-loss program for an unrelated reason (very unlikely), or (c) the user develops a metabolic or renal condition requiring it. The injectable route has theoretical appeal (TMAO bypass, higher bioavailability) but the user already has an oral protocol option (ALCAR) with TMAO mitigation built in.

  • 30-50, executive maintenance
    WATCH-LIST

    Same logic; possibly worth considering during specific weight-loss campaigns alongside GLP-1 if a clinic program is in play. Otherwise oral wins.

  • 50+, mild cognitive decline
    SKIP

    for parenteral. ALCAR oral has the MCI evidence base; injectable form has no specific cognitive trial advantage.

  • Anxiety-prone
    SKIP

    Mild restlessness/overstimulation possible at high doses; no anxiolytic indication.

  • High athletic load, drug-tested status
    OK

    if needed (NOT WADA-prohibited as of 2026). Confirm via WADA prohibited list before any competition; current status is unrestricted. Plain L-carnitine (any route) is not on WADA's prohibited list.

  • Sleep-disordered
    OK

    unlike ALCAR, plain injectable L-carnitine has no characteristic stimulating effect; PM dosing is unproblematic.

  • Recovery-focused (post-injury, post-illness)
    NOT THE RIGHT TOOL

    BPC-157, TB-500, GHK-Cu cover this lane; carnitine is a metabolic cofactor not a healing peptide.

  • Strength/anabolic-focused
    OPTIONAL-ADD

    orally; SKIP injectable. L-carnitine-tartrate (LCLT) oral 2-3 g/day has a body of evidence for muscle recovery; injectable adds nothing.

  • Endurance
    OPTIONAL-ADD

    orally; SKIP injectable. Same logic.

  • Documented primary carnitine deficiency (very rare)
    STANDARD OF CARE

    IV Carnitor. Lifelong indication.

  • ESRD on hemodialysis
    STANDARD OF CARE

    IV after each dialysis session. Per nephrologist.

  • Acute valproate toxicity
    STANDARD ANTIDOTE

    IV per protocol. ED / inpatient setting.

  • Hypothyroid on T4/T3 replacement
    CAUTION

    L-carnitine antagonizes thyroid hormone action; drop or expect dose titration.

  • Bipolar / psychotic-spectrum
    CAUTION

    Less well-characterized for plain L-carnitine than for ALCAR (which has documented mania case reports), but theoretical concern persists.

  • Seizure history
    AVOID

    Reported risk of seizure exacerbation; hard-blocked in frontmatter.

▸ Subjective experience (deep)

For the off-label clinic context (1-2 g IM weekly):

  • Onset: Within hours of injection most users report a mild "energy" feeling — typically driven by B-vitamin co-formulations and placebo, not by L-carnitine itself. Pure L-carnitine IM (no co-formulation) is largely subjectively silent.
  • First week: Bright yellow urine (riboflavin from blend formulations), mild injection-site bruising or stinging (~30% incidence per Lipo-C pep-pedia data), occasional fishy body odor (TMA from carnitine that escapes mitochondrial uptake — less common with IM than oral but still possible).
  • Weeks 2-4: No characteristic subjective effect from carnitine alone. Any visible body composition change is dominated by concurrent caloric deficit / GLP-1 / training program. Honest patients on placebo-blinded MIC injections have reported similar "energy" effects.
  • Weeks 4-12: Plateau. If no measurable benefit by week 8-12, discontinuation is appropriate.
  • Off-cycle: Plasma carnitine returns to baseline over 1-2 weeks (renal clearance is efficient when sodium-dependent reabsorption is saturated). No withdrawal pattern, no rebound.

Reality check: the strongest subjective signal is in users who happen to have an unrecognized B12 deficiency (real correction → real energy improvement) or who use the clinic visit as a forcing function for diet adherence. The carnitine itself, in lean replete users, produces no characteristic felt experience.

▸ Tolerance + cycling deep dive
  • Tolerance buildup: Minimal. Carnitine is a substrate-replenishment intervention, not a receptor-targeting drug — there is no receptor to downregulate. Plasma half-life ~17 hours; tissue half-life days-to-weeks.
  • Recommended cycle:
    • Off-label clinic use: 8-12 weeks on, 4 weeks off to verify benefit attribution.
    • FDA-approved Rx use: indefinite — these are chronic conditions.
  • Reset protocol if needed: Not really applicable — there's no pharmacological reset. If a cycle didn't produce results, the more useful question is "is this the right tool for this problem?" not "do I need a longer washout?"
  • Re-cycling: Safe to repeat. Most clinic patients run intermittent cycles aligned with weight-loss program phases.
▸ Stacking deep dive

Synergistic with

  • citrulline-malate — Both support exercise performance via different mechanisms (NO-mediated vasodilation + mitochondrial fatty-acid oxidation). Citrulline 6-8 g pre-workout + L-carnitine timing-flexible. Reasonable PRN combination for endurance work; injectable carnitine specifically has no advantage over oral for this purpose.
  • Coenzyme Q10 — Supports electron transport chain downstream of fatty-acid oxidation. Combined mitochondrial energy support is studied in cardiac and statin-myopathy contexts. Oral CoQ10 100-200 mg/day pairs with any carnitine route.
  • Omega-3 fatty acids — L-carnitine transports fatty acids including omega-3 EPA/DHA into mitochondria; combination plausibly increases CPT-I activity. Already covered by V4 fish oil; injectable carnitine adds nothing oral can't do for this synergy.
  • Alpha-lipoic acid (R-ALA) — Antioxidant + mitochondrial cofactor; classic neuropathy-adjacent stack with ALCAR. Oral 600 mg/day is the trial dose; injectable form unnecessary.
  • GLP-1 agonists (semaglutide, tirzepatide) — Different mechanisms (appetite suppression vs fatty-acid mitochondrial transport); commonly co-administered in clinic weight-loss programs. No direct pharmacological synergy but no conflict either; if a clinic program is the context, the GLP-1 is doing the heavy lifting for fat loss and the carnitine is adjunct cofactor.

Avoid stacking with

  • alcar (oral acetyl-L-carnitine) — Redundant carnitine loading. Oral ALCAR + IM L-carnitine produces additive plasma carnitine levels without therapeutic advantage; users get the TMAO bump from the oral fraction without escaping it via the IM route. Pick one route. For the user archetype, oral ALCAR at 500 mg AM is the cleaner choice given 1/100th cost and equivalent CNS penetration.
  • lipo-c (MIC + carnitine "MICC" formulations) — Lipo-C in MICC variants already contains 100-200 mg L-carnitine per mL; adding standalone IM L-carnitine duplicates the active component without rationale and stacks B-vitamin loads.
  • fat-blaster — Same overlap concern as Lipo-C; Fat Blaster contains 300 mg L-carnitine per 1 mL plus MIC + B-complex. Stacking standalone IM L-carnitine doubles up the carnitine while exposing the user to Fat Blaster's B6 toxicity ceiling at chronic high-frequency use.
  • High-dose thyroid replacement (levothyroxine, T3, NDT) — Benvenga 2004 documented L-carnitine antagonism of T3/T4 nuclear entry. Therapeutic for hyperthyroid symptom control; problematic for hypothyroid users requiring replacement. Drop carnitine or expect to titrate thyroid dose up.

Neutral / safe co-administration

  • All canonical V4 stack items: DHA, Magtein, citicoline, NAC, PS, Mg glycinate, curcumin phytosome, rhodiola, L-theanine, glycine/L-tryptophan, D3+K2, beta-alanine, vitamin C, creatine.
  • BPC-157, TB-500, GHK-Cu — no pathway overlap; no reported interactions.
  • Modafinil, racetams, Russian peptides (Semax, Selank, Bromantane) — different lanes, no interactions.
  • TRT or HRT — HPG-axis-neutral, no interactions.
▸ Drug interactions deep dive
  • Levothyroxine / T3 / NDT — Benvenga 2004: L-carnitine 2-4 g/day antagonizes thyroid hormone nuclear entry. Real interaction — therapeutic for hyperthyroidism, problematic for hypothyroid patients on replacement. Action: if on thyroid replacement, drop carnitine or expect dose titration up at next labs.
  • Warfarin — Case reports of mild potentiation of anticoagulant effect; mechanism unclear. Action: baseline INR + recheck 1-2 weeks after starting injectable carnitine at therapeutic dose.
  • Valproic acid (sodium valproate, valproate semisodium) — Therapeutic synergy for valproate-induced carnitine depletion (see Indications); no adverse interaction.
  • Pivalate-containing antibiotics (pivampicillin, pivmecillinam) — These deplete carnitine via urinary pivaloylcarnitine excretion; carnitine supplementation corrects this. Rare in modern US prescribing.
  • Nucleoside reverse-transcriptase inhibitors (zidovudine, stavudine, didanosine) — Carnitine is used to treat their associated mitochondrial toxicity neuropathy. Synergistic, not adverse.
  • Anticonvulsants other than valproate — Phenytoin, carbamazepine, and phenobarbital can mildly reduce carnitine levels; the clinical significance for healthy users is minimal.
  • CYP enzymes — No significant induction or inhibition reported. L-carnitine does not meaningfully alter pharmacokinetics of CYP-metabolized drugs.
  • Hormonal contraceptives — No interaction reported.
▸ Pharmacogenomics

SLC22A5 (OCTN2 — primary carnitine transporter)

  • Loss-of-function homozygous = primary systemic carnitine deficiency (rare, severe, FDA-approved indication for IV Carnitor).
  • Heterozygous variants more common; modulate tissue carnitine distribution and may affect response to supplementation. Not actionable for healthy users without symptoms.
  • 23andMe parsing (the user's results due ~June 5-15): SLC22A5 is on most pharmacogenomic panels; rare loss-of-function variants flagged automatically. For the user archetype with no carnitine deficiency symptoms, expected to be wild-type.

FMO3 (Flavin-Containing Monooxygenase 3)

  • Critical for oral carnitine — oxidizes gut-derived TMA → TMAO. Hypomorphic variants (rs2266782 E158K, rs2266780 V257M, rs1736557 E308G) reduce TMA → TMAO conversion and produce "fish odor syndrome" (TMAU) at high carnitine/choline loads.
  • For injectable carnitine specifically: FMO3 is largely irrelevant because IM bypasses gut bacterial TMA production. This is one mechanistic argument for IM > oral in users with FMO3 hypomorphs who get fishy body odor on oral carnitine.

TMLHE / BBOX1 (carnitine biosynthesis)

  • Polymorphisms reduce endogenous L-carnitine synthesis. Rare; relevant in autism research literature (TMLHE deficiency). May benefit more from supplementation but no IM-specific data.

CHRNA4, CHRM1 (cholinergic receptors)

  • Theoretical relevance for ALCAR (acetyl group → acetylcholine pathway). For plain L-carnitine, minimal relevance — the carnitine moiety is the active fraction, not the acetyl.
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
FDA-approved IV (Rx) Carnitor (Sigma-Tau / Leadiant) ~$50-150 per 1 g / 5 mL ampule via specialty pharmacy; insurance-covered for FDA indications Highest Reference standard for IV carnitine. Requires prescription + indication on label (PCD or ESRD). Hospital + dialysis-unit standard.
503A/503B compounded Reputable PCAB pharmacy (e.g., Olympia, Empower, Strive) $40-120 per 5-10 mL multi-dose vial High Used by weight-loss clinics for IM/SC off-label dosing. Requires Rx from compounding-pharmacy-aligned provider. PCAB accreditation + sterility/endotoxin COA per lot.
Weight-loss clinic / med-spa Various $25-75 per 1 mL injection ($100-300/month at weekly cadence) Variable Includes provider visit + injection administration. Quality of compounding pharmacy supply varies; ask which compounder.
Telehealth peptide clinic Various $150-400/month Medium Some clinics in non-FDA-aligned regulatory zones still prescribe. Quality varies wildly. Verify compounding pharmacy.
Research-chem peptide vendor NOT RECOMMENDED $20-50 per 5 mL vial Low for parenteral safety Some peptide vendors sell "L-carnitine injectable" without sterility/endotoxin documentation. Not appropriate for IM/SC use. The legitimate IV form (Carnitor) is FDA-approved and available cheaply through legitimate channels — gray-market sourcing has zero legitimate indication. Skip.

Verification protocol if pursuing legitimate parenteral carnitine:

  1. Request compounding pharmacy 503A/503B documentation + lot-specific COA showing sterility + endotoxin testing (<0.5 EU/mg).
  2. Visual inspection: clear, colorless to slightly yellow solution, no particulates, no cloudiness.
  3. Multi-dose vial: store per pharmacy beyond-use dating after first puncture (typically 28 days refrigerated for bacteriostatic-preserved product).
  4. Single-dose ampule: use within session after opening.

Cost comparison vs oral L-carnitine:

  • Oral L-carnitine (NOW Foods, Doublewood, etc.) at 1.5-2 g/day: ~$15-25/month.
  • Clinic IM L-carnitine at 1-2 g/week: ~$100-300/month + provider visit fees.
  • Cost differential: ~10-20× for the injection route, with no demonstrated body-composition advantage in any head-to-head trial. This is the core economic argument against off-label IM use in healthy young athletes.
▸ Biomarkers to track (deep)

Baseline (before starting)

  • Free + total carnitine (plasma), urinary carnitine — establishes whether deficiency exists. Most healthy omnivores are replete; vegans/vegetarians can be marginally low. Free carnitine <40 µmol/L flags deficiency.
  • Lipid panel (total chol, LDL, HDL, ApoB, Lp(a)) — baseline cardiovascular risk picture.
  • TMAO (Cleveland HeartLab or equivalent) — useful comparator if switching from oral to IM as a TMAO-reduction strategy.
  • hs-CRP — baseline inflammation.
  • TSH, free T3, free T4 — thyroid baseline (interaction relevant).
  • CBC, CMP — general baseline + liver/kidney function.
  • DXA or comparable body composition assessment — if weight-loss adjunct is the indication, hard endpoint matters.
  • HbA1c, fasting glucose, fasting insulin — metabolic baseline.

During use

  • Subjective tracking: energy, body composition, exercise capacity — daily 1-10 ratings for first 4 weeks, then weekly.
  • Body composition at week 4, 8, 12 if weight-loss adjunct.
  • TMAO at week 8 if switching from chronic oral carnitine to IM as a TMAO-mitigation move — should drop substantially.
  • Lipid panel + hs-CRP at week 12.
  • Free carnitine repeat if treating documented deficiency or ESRD — titrate to >40 µmol/L.
  • Body odor self-monitor — TMAU symptom check.

Post-cycle (if cycled off)

  • Subjective + body composition reassessment at 4-week washout — verify any benefit was attributable to the carnitine vs concurrent program elements.
  • TMAO at end of washout — confirm baseline.
▸ Controversies / open debates Live debate

  1. Off-label IM/SC clinic use vs oral. No head-to-head IM-vs-oral RCT for body composition or athletic performance exists. The clinic argument rests on bioavailability (real, but fixable with adequate oral dose) and adherence (real, but a confounded mechanism — paying for clinic visits drives diet adherence regardless of what's in the syringe). Critics argue the IM clinic protocol is an expensive placebo + accountability device; defenders argue mild objective benefit on top of placebo + adherence is still a benefit. My read: in healthy young adults with no deficiency, the oral form covers 95%+ of legitimate use cases, and the IM form's pricing premium (~10-20×) is not justified by the data.

  2. TMAO and cardiovascular risk. Whether TMAO is causally atherogenic or merely a marker is debated. Mechanistic case is strong (foam-cell formation, platelet hyperreactivity); epidemiology consistent but confounded by red-meat dietary patterns. Consensus 2025: TMAO is at minimum a strong risk marker and probably causal at high chronic levels. This is the single strongest mechanistic argument for IM > oral in users who genuinely need chronic high-dose carnitine. For users who don't need chronic high-dose carnitine, the answer is to not take it chronically rather than to upgrade the route.

  3. Cardiac mortality benefit in MI: real or publication artifact? DiNicolantonio 2013 Mayo meta showed dramatic post-MI mortality benefit; 2018 Cochrane review was less impressed, citing bias risk and modest absolute effect sizes. The Italian RCT corpus that drives DiNicolantonio's positive estimates may not generalize. Standard cardiac care has improved enormously since the 1990s when most of these trials ran — the absolute benefit of carnitine on top of modern post-MI care is unknown.

  4. Carnitine for healthy athletes — is there any signal? Trials in trained athletes have been mostly null. Anecdotal community reports are mixed-to-positive. Best read: real but small effect, with high inter-individual variability driven by baseline carnitine status. Lean omnivorous athletes are usually carnitine-replete via dietary red meat; supplementation produces marginal upside. Vegan endurance athletes may benefit more.

  5. Quality of clinic compounding pharmacy supply chain. PCAB-accredited 503A/503B compounders are well-regulated and produce reliable product. Non-accredited compounders and gray-market peptide vendors selling "injectable L-carnitine" are not appropriate for parenteral use. The legitimate IV form (Carnitor) is FDA-approved generic — there is no good reason to source from anywhere but a legitimate pharmacy channel.

  6. Seizure risk. Case reports in epilepsy patients of L-carnitine increasing seizure frequency. Mechanism unclear. Conservative move: hard-block seizure history. The valproate-toxicity indication is paradoxical here — seizure patients on valproate often need carnitine — but those decisions should be made by a neurologist, not a self-experimenter.

▸ Verdict change log
  • 2026-05-10 — Initial verdict: WATCH-LIST. For a healthy 20yo MMA athlete, parenteral L-carnitine has no advantage over oral L-carnitine / ALCAR that justifies the ~10-20× cost premium and the additional injection burden. The legitimate parenteral indications (PCD, ESRD, valproate toxicity) are clinical scenarios that don't apply to the user. The TMAO-bypass argument is real but addresses a problem the user can solve more cheaply with oral cycling + dietary mitigation. Verdict re-evaluates if (a) June bloodwork shows carnitine deficiency, (b) entry into a clinical weight-loss program changes context, or (c) head-to-head IM-vs-oral RCT for body composition emerges showing meaningful incremental benefit. Confidence HIGH because the case for parenteral in this archetype is weak across multiple independent analyses (cost, evidence, mechanism, available alternatives).
▸ Open questions / gaps Open
  1. Head-to-head IM-vs-oral RCT for weight loss — does not exist. The clinic IM protocol's claim to advantage over oral 2 g/day has never been tested.
  2. IM-vs-oral comparison on TMAO trajectory in users with FMO3 hypomorphs — would establish whether IM is the appropriate substitute for users who can't tolerate oral. Plausible but not directly tested.
  3. Long-term IM safety — most IM clinic protocols are 8-12 week cycles; cumulative chronic IM safety beyond 1 year is not characterized in healthy users.
  4. Whether IM L-carnitine has any specific sport-performance advantage in lean trained athletes — not characterized; available trials are in older or metabolically stressed populations.
  5. Cost-effectiveness vs equivalent oral protocols — formal pharmacoeconomic analyses don't exist; the clinic premium is justified by bioavailability claims that are real but not necessarily clinically meaningful at adequate oral dose.
  6. 23andMe SLC22A5 variants — for the user, due ~June 2026; if rare loss-of-function variants emerge, the calculus shifts toward parenteral consideration.

References

Pooyandjoo M, Nouhi M, Shab-Bidar S, et al. 2020 — L-Carnitine for weight loss meta (PMID 31465723)

pubmed.ncbi.nlm.nih.gov · 2020

37-RCT meta-analysis (n=2,292) showing ~1.21 kg weight loss + 2.1 kg fat-mass reduction at oral 1.5-3 g/day.

View Study

Hathcock JN, Shao A 2006 — Risk Assessment for Carnitine (PMID 16766096)

pubmed.ncbi.nlm.nih.gov · 2006

Regulatory toxicology review establishing observed safe level (~2 g/day oral).

View Study

Brass EP 2002 — Carnitine in End-Stage Renal Disease (PMID 12500225)

pubmed.ncbi.nlm.nih.gov · 2002

Foundational ESRD review establishing FDA-approved IV carnitine rationale.

View Study

DiNicolantonio JJ, Lavie CJ, Fares H, et al. 2013 — L-Carnitine in Secondary Prevention of CVD (PMID 23597877)

pubmed.ncbi.nlm.nih.gov · 2013

Mayo Clin Proc meta of 13 trials showing post-MI mortality benefit.

View Study

Bain MA, Milne RW, Evans AM 2006 — Disposition and metabolite kinetics of oral L-carnitine (PMID 16638967)

pubmed.ncbi.nlm.nih.gov · 2006

Pharmacokinetic study of ~14-18% oral bioavailability and ~17h plasma half-life.

View Study

Carnitor (levocarnitine injection) FDA Label

accessdata.fda.gov

FDA-approved indications, dosing, and pharmacokinetics for IV levocarnitine.

View Source

WADA 2026 Prohibited List

wada-ama.org · 2026

confirms L-carnitine not prohibited (any route, any form).

View Source

Examine.com L-Carnitine research breakdown

examine.com

third-party evidence synthesis.

View Source

Cochrane Review: L-carnitine for acute MI (2018)

cochranelibrary.com · 2018

more conservative read on cardiac mortality benefit relative to DiNicolantonio.

View Source

How was your experience with this compound?

Anonymous · one vote per session · results below at 5+ votes.

Loading…
✎

See something off?

Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.

Discussion — click to load ▸
Loading…